RESEARCH ARTICLE

REVISED Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia [version 3; peer review: 2 approved, 1 approved with reservations]

Siprianus Ugroseno Yudho Bintoro ^{1,2}, Ni Made Intan Dwijayanti^{1,2}, Dana Pramudya², Putu Niken Amrita ^{1,2}, Pradana Zaky Romadhon ^{1,2}, Tri Pudy Asmarawati ^{2,3}, Arief Bachtiar^{2,4}, Usman Hadi ^{2,3}

¹Hematology – Medical Oncology Division, Department of Internal Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia

²Dr. Soetomo General Teaching Hospital, Surabaya, East Java, 60286, Indonesia

³Tropical and Infectious Diseases Division, Department of Internal Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia

⁴Department of Pulmonology and Respiratory Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia

V3 First published: 11 Aug 2021, 10:791
<https://doi.org/10.12688/f1000research.53803.1>
 Second version: 21 Sep 2021, 10:791
<https://doi.org/10.12688/f1000research.53803.2>
 Latest published: 29 Nov 2021, 10:791
<https://doi.org/10.12688/f1000research.53803.3>

Abstract

Background : This research aimed to examine and analyze risk factors for death, hematologic parameters and coagulation in COVID-19 patients at RSUD Dr. Soetomo Surabaya, one of the referral centers for probable COVID-19 patient cases in East Java.

Method : This was a retrospective analytical study by taking secondary data on patients with probable COVID-19 cases who were treated in hospital isolation rooms from May to September, 2020.

Result : Of 538 probable COVID-19 patients, 217 were tested positive, with an average age of 52.11 ± 13.12 years, and there were 38 death cases. Hematologic parameters, such as white blood cell, neutrophil and lymphocyte counts, showed significantly different result in the deceased group. On the other hand, coagulation parameters, consisting of D-dimer, CRP, PT, and aPTT showed significantly similar value in the deceased group. Univariate analysis concluded that chronic kidney disease, diabetes mellitus, coronary heart disease, WBC, NLR, and PPT counts could predict the mortality, while multivariate analysis revealed that coronary heart disease was the

Open Peer Review

Approval Status

	1	2	3
version 3 (revision) 29 Nov 2021		view	view
version 2 (revision) 21 Sep 2021	view		view
version 1 11 Aug 2021	view	view	

1. **Andhika Rachman** , University of Indonesia, Jakarta, Indonesia
Bayu Rumondor, Kebayoran Baru General Hospital Jakarta, South Jakarta, Indonesia

only significant independent predictor of mortality.

Conclusion : This research shows that hematologic and coagulation parameters increased in the majority of COVID-19 patients and the deceased group. While the number of neutrophils and WBC increases, the number of lymphocytes decreases significantly as the disease gets more severe.. Coronary heart disease is an independent predictor of mortality.

Keywords

COVID-19, comorbid, hematology, coagulopathy, good health, and well-being

This article is included in the **Emerging Diseases and Outbreaks** gateway.

This article is included in the **Coronavirus** collection.

2. **Azlan Bin Husin** , Hospital Universiti Sains Malaysia, Kubang Kerian, Malaysia
Universiti Sains Malaysia, Kubang Kerian, Malaysia

3. **Simona Lattanzi** , Marche Polytechnic University, Ancona, Italy

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding authors: Siprianus Ugroseno Yudho Bintoro (ugroseno@fk.unair.ac.id), Usman Hadi (usman.hadi2@fk.unair.ac.id)

Author roles: **Bintoro SUY:** Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Review & Editing; **Dwijayanti NMI:** Data Curation, Formal Analysis, Investigation, Project Administration, Software, Visualization, Writing – Original Draft Preparation; **Pramudya D:** Conceptualization, Formal Analysis, Project Administration, Resources, Visualization, Writing – Review & Editing; **Amrita PN:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Romadhon PZ:** Investigation, Methodology, Project Administration, Software, Validation, Visualization, Writing – Original Draft Preparation; **Asmarawati TP:** Conceptualization, Data Curation, Investigation, Methodology, Project Administration, Resources, Validation, Visualization, Writing – Original Draft Preparation; **Bachtiair A:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation; **Hadi U:** Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: Universitas Airlangga COVID-19 Grant 2020

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Bintoro SUY *et al.* This is an open access article distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Bintoro SUY, Dwijayanti NMI, Pramudya D *et al.* **Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia [version 3; peer review: 2 approved, 1 approved with reservations]** F1000Research 2021, 10:791 <https://doi.org/10.12688/f1000research.53803.3>

First published: 11 Aug 2021, 10:791 <https://doi.org/10.12688/f1000research.53803.1>

REVISED Amendments from Version 2

In this revised version, we added the detail of the hospital admission criteria: a patient who was confirmed or suspected with COVID-19, who are symptomatic, plus any of the following criteria that has been mentioned.

This version explains the significance of the age factor also correlates with the age-dependent defects in T-cell and B-cell function that could lead to a deficiency in control of viral replication and more prolonged proinflammatory responses, potentially leading to poor outcomes.

This version also mentions the cut-off point of D-Dimer level to predict mortality and its comparison within several studies.

Any further responses from the reviewers can be found at the end of the article

Introduction

In December 2019, China reported a mysterious pneumonia case of unknown cause which had spread rapidly in Wuhan city. The World Health Organization (WHO) named this virus as the 2019 novel coronavirus (2019-nCoV),^{1,2} and the name was changed to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) by the Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses; the official name of the disease caused by the virus is COVID-19.^{2,3} COVID-19 is a major health concern at this time, especially for the elderly, due to the SARS-CoV-2 virus.^{4,5} This coronavirus has become the main pathogen, causing an outbreak of respiratory disease until it has been declared a pandemic, and spreading rapidly throughout the world, including Indonesia.⁶ COVID-19 has become a global problem today due to the high transmission and mortality rates.⁷

As reported by Huang *et al.*, patients with COVID-19 present primarily with fever, myalgia or fatigue, and dry cough.⁷ Although most patients are considered to have good prognoses, elderly patients, as well as those with underlying chronic conditions, may have worse outcomes. Severe patients may experience shortness of breath and hypoxemia within one week of disease onset, which can rapidly progress to acute respiratory distress syndrome (ARDS) or end-organ damage. Chronic cardiac and metabolic disease, the presence of acute inflammation as well as decreased organ (heart, kidney, liver, and hematology) function experienced by patients at the beginning of treatment, can increase the risk of death due to COVID-19 infection.^{8,9}

The need for COVID 19 patients to be hospitalized varies widely from country to country as it depends on the prevalence of community testing and admission criteria.^{2,10} However, it is estimated that one in 5–10 adult patients with disease severity and sufficient criteria to be hospitalized. Most of the patients with severe acute respiratory infections or severe acute respiratory syndrome were managed according to the case definition of WHO. The criteria for intensive care also vary from country to country. Old age, chronic disease, and male gender consistently associated with increased mortality.¹⁰

Hematologic and coagulation parameters were important for predicting the severity of COVID-19. The occurrence of disseminated intravascular coagulation (DIC) is a common finding in COVID-19 patients.¹¹ In addition, administering anticoagulant therapy to high-risk patients is effective in reducing mortality.^{12,13}

The first COVID-19 case in Indonesia was announced on March 2, 2020, four months after the first case in China.¹⁴ The first cases in Indonesia in March 2020 were two cases; and after that, two cases were noted on March 6th. COVID-19 cases continue to grow. In the beginning, there were hundreds of cases added; and until now, the number of cases has increased to thousands. On March 17, 2020, the government of East Java reported the first case of COVID-19, and as of July 31, 2020, there were 22,098 confirmed cases with a fairly high mortality rate of 7.6%.¹⁶ Meanwhile, in July 2020, Surabaya reported 8,691 confirmed COVID-19 patients. The RSUD Dr. Soetomo (RSDS) Surabaya is one of the referral centres for probable COVID-19 patient cases in East Java. Based on the total cases, it is necessary to collect data, including clinical manifestations, risk factors, hematologic parameters, and coagulation which aggravate the condition of COVID-19 patients.¹⁷

Several studies related to clinical manifestations and risk factors for COVID-19 patients have been reported previously; however, this research is based on relatively small sample size, and the risk factors that lead to poor clinical outcomes have not yet been well explained. In addition, probable and confirmed cases of COVID-19 at RSDS Surabaya had often presented with comorbidities, such as diabetes mellitus, high blood pressure, heart disease, hematological disorders, old age, chronic lung disease, stroke, and kidney disorders. This leads to discussion about which comorbid, hematologic parameters and coagulation factors may become predictive of COVID-19 mortality.

Methods

This was a retrospective analytical study, performed by taking secondary data on patients with probable COVID-19 cases who were treated at the special isolation room (non-intensive care) of the Department of Internal Medicine of the teaching hospital of RSUD Dr. Soetomo between May and September, 2020. The sample consisted of deceased and survived patients at the special isolation room (non-intensive care) of Internal Medicine of RSUD Dr. Soetomo, who had been hospitalized with probable COVID-19. Inclusion criteria probable COVID-19 patients were aged more than 18 years old, showing clinical signs of pneumoniae. They are categorized into moderate pneumoniae with signs and symptoms as follows: fever, cough, dyspnea, tachypnea, and later grouped into the severe category with additional criteria, such as: RR > 30 times per minute, O₂ sat <93% room air, also no mechanical support and ICU care needed. Patients with incomplete data were excluded.

According to hospitalized probable COVID-19 criteria, there were 538 probable cases. COVID-19 was diagnosed through sample taken from nasal swab and further RT PCR examination. 297 patients showed positive result, whereas the rest are negative. Of 297 patients, 80 had incomplete medical record, hence, 217 samples left eventually were included (see [Figure 1](#)).

Approval from the local ethics committee was obtained for this research; written informed consent was obtained from patients during hospitalization. From the hospital information database system, we retrieved patient characteristics such as age, gender, comorbidities, signs and symptoms, and laboratory results, including hemoglobin, white blood cell (WBC), neutrophil, lymphocyte, and platelet counts, D-dimer level, C-reactive protein (CRP), prothrombin time (PT), and activated partial thromboplastin time (aPTT).

Figure 1. Patient COVID-19 data selection process.

Table 1. Laboratory and clinical overview of the deceased and survived patients.

	Total (n = 217)	Survival status		p-value
		Not survive (n = 38)	Survive (n = 179)	
Age	52.11 ± 13.12	58.42 ± 12.78	50.77 ± 12.83	<0.001
Gender				
Male	116 (53.5)	23 (60.5)	93 (52.0)	0.336
Female	101 (46.5)	15 (39.5)	86 (48.0)	
Comorbid factors	129 (59.4)	28 (73.7)	101 (56.4)	0.049
Diabetes (DM)	72 (33.2)	18 (47.4)	54 (30.2)	0.041
Hypertension (HT)	66 (30.4)	13 (34.2)	53 (29.6)	0.575
Coronary heart disease	4 (1.8)	4 (10.5)	0 (0)	<0.001*
Thyroid	2 (0.9)	0 (0)	2 (1.1)	0.680*
Obesity	2 (0.9)	0 (0)	2 (1.1)	0.680*
Malignancy	10 (4.6)	4 (10.5)	6 (3.4)	0.076*
CKD	42 (19.4)	27 (15.1)	15 (39.5)	<0.001
Regular HD	11 (5.1)	9 (5.0)	2 (5.3)	0.605*
Hepatitis B	7 (3.2)	4 (2.2)	3 (7.9)	0.105*
Chronic liver disease	5 (2.3)	3 (1.7)	2 (5.3)	0.211*
Chronic lung disease	5 (2.3)	0 (0)	5 (2.8)	0.378*
Symptoms				
Short of breath	118 (54.4)	25 (65.8)	93 (52.0)	0.120
Cough	111 (51.2)	19 (50.0)	92 (52.4)	0.876
Fever	87 (40.1)	19 (50.0)	68 (38.0)	0.170
Limp	51 (23.5)	11 (28.9)	40 (22.3)	0.383
Hoarseness	0 (0)	0 (0)	0 (0)	-
Anosmia	2 (0.9)	0 (0)	2 (1.1)	0.680*
Nasal congestion	1 (0.5)	0 (0)	1 (0.6)	0.825*
Watery eyes	0 (0)	0 (0)	0 (0)	-
Muscle pain	0 (0)	0 (0)	0 (0)	-
Diarrhea	25 (11.5)	4 (10.5)	21 (11.7)	0.833
Swallowing pain	9 (4.1)	2 (5.3)	7 (3.9)	0.705
Headache	5 (2.3)	1 (2.6)	4 (2.2)	0.883
COVID-19 therapies				
Hydroxychloroquine	35 (16.1)	2 (5.3)	33 (18.4)	-
Isoprinosine	25 (11.5)	6 (15.8)	19 (10.6)	-
Oseltamivir	14 (6.5)	13 (7.3)	1 (2.6)	-
Lopinavir	38 (17.5)	11 (28.9)	27 (15.1)	-
Favipiravir (Avigan)	2 (0.9)	0 (0)	2 (1.1)	-
Laboratory parameters				
Hb (g/dL)	12.27 ± 2.54	11.75 ± 2.30	12.38 ± 2.58	0.075**
WBC (×10 ⁹ /L)	10.83 ± 9.64	13.67 ± 11.83	10.23 ± 9.03	0.011**
Neutrophil abs (×10 ⁹ /L)	8.19 ± 7.39	13.67 ± 11.13	10.23 ± 6.16	0.002**
Lymphocyte abs (×10 ⁹ /L)	1.46 ± 1.34	1.39 ± 1.54	1.48 ± 0.11	0.074**
NLR	8.53 ± 17.87	15.57 ± 39.14	7.04 ± 7.51	0.003**

Table 1. Continued

	Total (n = 217)	Survival status		p-value
		Not survive (n = 38)	Survive (n = 179)	
PLT count ($\times 10^9/L$)	298.87 $\pm$ 174.02	315.28 $\pm$ 253.73	295.39 $\pm$ 152.63	0.953**
aPTT (second)	28.82 $\pm$ 9.14	31.37 $\pm$ 17.40	28.28 $\pm$ 6.07	0.635**
PPT (second)	12.58 $\pm$ 6.81	15.06 $\pm$ 14.27	12.06 $\pm$ 3.52	0.103**
D-Dimer (ng/dL)	3593.15 $\pm$ 5380.45	6767.55 $\pm$ 8655.18	2919.26 $\pm$ 4117.03	<0.001**
CRP (mg/dL)	12.95 $\pm$ 45.54	17.80 $\pm$ 11.55	11.92 $\pm$ 49.83	<0.001**

*Fischer Exact test.

**Mann-Whitney test.

Statistical analysis

Data analysis was performed using SPSS version 25 (Chicago, IL, USA; RRID:SCR_002865); JASP (RRID:SCR_015823) is an open access alternative. Patient characteristics (see Table 1) are presented as mean $\pm$ standard deviation or median, and interquartile ranges of 25th and 75th percentiles (IQR 1–3) or minimum and maximum, depending on the continuous distribution variable. Normality tests were performed and a comparison test for normal distribution data by an independent sample t-test and a Mann–Whitney test, otherwise. We used ANOVA to determine statistical differences among some groups with normally-distributed data. contrarily, we carried out Kruskal Wallis analysis in groups with abnormally distributed ones. Comparison for the categorical variables were performed using Pearson's and Fisher's Exact Chi-squared tests. Survival analyses and Kaplan–Meier survival curves were performed for hemoglobin, white blood cell, neutrophil, lymphocyte, neutrophil–lymphocyte ratio, D-dimer, PT, aPTT, and CRP.

The evaluation of independent predictors of mortality was performed by univariate and multivariate Cox regression analysis. Threshold mortality predictor from the laboratory parameter was also performed; the receiver–operating curve (ROC) analysis associated with the area under the curve (AUC) was used to find the optimal threshold value of the laboratory rate parameter to predict the progression of mortality in the study group. The AUC was interpreted as excellent if $0.9 < \text{AUC} < 1$; good if $0.8 < \text{AUC} < 0.9$; moderate if $0.7 < \text{AUC} < 0.8$; poor if $0.6 < \text{AUC} < 0.7$; and fail if $0.5 < \text{AUC} < 0.6$.

Results

538 patients with probable COVID-19 were included during the study period in which. 288 (53.5%) were males, with the mean $\pm$ SD age of 51.69 $\pm$ 13.67 years. More than half of the patients (63.7%) had elemental diseases, including diabetes mellitus (34%), hypertension (32.5%), and CKD (22.7%). All the patients with probable COVID-19 experienced symptoms on arrival, including complaints of shortness of breath (48.7%), cough (40%), fever (32%), and limp (24%). Some patients also complained of diarrhea and headache but it was only at 10.2% and 3.2%, respectively.

Demographic and clinical overview and laboratory results of the COVID-19 patient study group

In total, we included 217 hospitalized patients with a diagnosis of COVID-19; they were 116 male patients and the male-to-female ratio was 1.14. The average age of this retrospective research was 52.11 $\pm$ 13.12 years. The most common chronic disease (comorbid) among patients was diabetes (33.2%). The clinical and demographic characteristics and laboratory results are shown in Table 1.

Comparison of laboratory parameters in deceased and survived patients

From 217 patients, 38 patients (17.5%) died. They were significantly older than those who survived (mean 58.42 $\pm$ 12.78 versus 50.77 $\pm$ 12.83 years, respectively; $p < 0.001$). The majority of the deceased patients had at least one comorbidity (73%), while 56.4% of the patients who survived had comorbid factors ($p = 0.049$). The common comorbidities that were significantly different were diabetes mellitus, hypertension, and coronary heart disease in the group of deceased patients than in those who survived. We stratified laboratory markers that we divided based on normal lab values. In deceased patients, the white blood cell, neutrophil, and lymphocyte counts showed significant difference between groups. Otherwise, D-dimer, CRP, PPT and aPTT did not show any differences (see Table 2).

Inflammatory markers (leukocyte, C-reactive protein, neutrophil count and NLR) were significantly higher in the deceased group than in the group who survived. While the normal leukocyte and neutrophil counts were significantly more common in the patients who survived, and lymphopenia was significantly more common in deceased patients ($p = 0.048$). Meanwhile, the frequency of thrombocytopenia and the increase in D-dimer were comparable between two groups. Neutropenia, leukopenia, lymphopenia, higher CRP, NLR, and PT correlated with COVID-19 patients' mortality.

Table 2. Comparison of laboratory results in deceased and survived patients.

	Total (n = 217)	Survival status		p-value
		Not survive (n = 38)	Survive (n = 179)	
Hemoglobin (g/dL) (%)				
<12	78 (35.9)	20 (52.6)	58 (52.4)	0.052*
12-16	136 (62.7)	18 (47.4)	118 (65.9)	
>16	3 (1.4)	0 (0)	3 (1.7)	
WBC (leucocyte) ($\times 10^9$) (%)				
<4.0	13 (6.0)	2 (5.3)	11 (6.1)	0.028
4.0-10.0	125 (57.6)	15 (39.5)	110 (61.5)	
>10.0	79 (36.4)	21 (55.3)	28 (32.4)	
Neutrophil count ($\times 10^9$) (%)				
<2.0	9 (4.1)	2 (5.3)	7 (3.9)	0.006
2.0-7.0	119 (54.8)	12 (31.6)	107 (59.8)	
>7.0	89 (41.0)	24 (63.2)	65 (36.3)	
Lymphocyte count ($\times 10^9$) (%)				
<0.8	47 (21.7)	12 (31.6)	35 (19.6)	0.048*
0.8-4.0	166 (76.5)	24 (63.2)	142 (79.3)	
>4.0	4 (1.8)	2 (5.3)	2 (1.1)	
Platelet count ($\times 10^9$) (%)				
<150	27 (12.4)	3 (7.9)	24 (13.4)	0.588*
150-450	164 (75.6)	31 (81.6)	133 (74.3)	
>450	26 (12.0)	4 (10.5)	22 (12.3)	
Above-normal result percentages				
C-reactive protein (%)	192 (88.5)	37 (97.4)	155 (86.6)	0.042
D-dimer (%)	203 (93.5)	36 (94.7)	167 (93.3)	0.543
Prothrombin time (%)	12 (5.5)	5 (13.2)	7 (3.9)	0.039
aPTT (%)	7 (3.2)	2 (5.3)	5 (2.8)	0.354
NLR	154 (71)	33 (86.8)	121 (67.6)	0.018

*Kruskal-Wallis test.

Neutrophil-lymphocyte ratio (NLR), Lactate dehydrogenase (LDH), International normalized ratio (INR), Activated partial thromboplastin time (aPTT). Normal laboratory reference values: CRP: 0–5mg /L, D-dimer: 0–500 ng/mL, PT: 11–16 seconds, aPTT: 25–40 seconds.

The ROC analysis using sensitivity and specificity based on mortality predictor revealed that there was an optimal cut-off value for several laboratory parameters including WBC count, neutrophil count, CRP level, D-dimer, and NLR count. The largest AUC value was CRP with a cut-off value of ≥ 1.85 (sensitivity = 94.7% and specificity = 72.1%). NLR, WBC count, neutrophil count, D-dimer, and CRP as mortality predictors showed good results (see [Table 3](#)).

Survival analysis

The Kaplan–Meier graph showed that leukocyte count, neutrophil count, NLR, PT, and CRP associated with patients mortality, that they can be used to predict it ($p < 0.05$, respectively) (see [Figure 2](#)). Moreover, lower survival rate was shown from leukopenia, leukocytosis, neutrophillia, high NLR, high CRP, and prolonged PT ($p = 0.015$; $p = 0.018$, $p = 0.003$, $p = 0.035$, and $p = 0.03$, respectively).

Determining independent predictors of mortality

We included age (as a categorical variable of under and over 65 years old), presence of chronic kidney disease, diabetes mellitus, coronary heart disease, and indicators, such as WBC count, NLR, CRP, PT, aPTT, and D-dimer for determining the predictors of mortality. In the univariate analysis, the independent predictors of mortality were shown from presence of chronic kidney disease, diabetes mellitus, coronary heart disease, WBC count, NLR, and PPT. However, based on the

Table 3. Sensitivity and specificity of laboratory parameters.

	AUC	Sensitivity	Specificity	Cut-off	95% CI	p-value
Hemoglobin (g/dL)	0.408	0.782	0.658	>10.85	0.311-0.505	0.075
WBC ($\times 10^9$)	0.631	0.620	0.737	≥ 7090	0.534-0.728	0.011
Neutrophil count ($\times 10^9$)	0.663	0.961	0.947	≥ 2080	0.570-0.756	0.002
Lymphocyte count ($\times 10^9$)	0.408	0.765	0.632	≥ 859	0.306-0.509	0.074
Platelet count ($\times 10^9$)	0.497	0.687	0.684	≥ 208000	0.401-0.593	0.953
C-reactive protein	0.773	0.947	0.721	≥ 1.85	0.693-0.852	<0.001
D-dimer	0.679	0.939	0.974	≥ 410	0.586-0.772	<0.001
Prothrombin time	0.584	0.877	0.895	≥ 9.95	0.476-0.692	0.103
aPTT	0.525	0.385	0.421	≥ 29	0.428-0.621	0.635
NLR	0.652	0.592	0.789	≥ 3.88	0.563-0.743	0.003

Cox multivariate regression analysis, only coronary heart disease significantly became the independent predictor of mortality (see Table 4).

Discussion

Significant differences were found in the demographic and clinical variables, and hematologic and coagulation parameters between the deceased and surviving COVID-19 patients. We included age in the risk factor for COVID-19 mortality, whereas the age had a p-value <0.05. The age factor appeared to be crucial for the outcome of COVID-19. The average age of the deceased patients was 58 years old and was significantly older than the surviving patients. This was in accordance with previous studies that older age has been reported as an important independent predictor of mortality in SARS-Cov2.^{15,16} Increasing age also increased the percentage of COVID-19 mortality, the age-dependent defects in T-cell and B-cell function could lead to a deficiency in control of viral replication and more prolonged pro inflammatory responses, potentially leading to poor outcome.¹⁷

Gender was proven to be a risk factor for mortality in COVID-19 patients, which was higher for men than for women. This is thought to be due to differences in the immunological systems of men and women, differences in lifestyle, and the prevalence of smoking.¹⁸ In this research, although statistically insignificant, the percentage of the number of male COVID-19 patients was higher, both overall and in the group of deceased patients. The higher mortality rates were associated with the higher chronic comorbidities in men, e.g., diabetes mellitus, kidney disease, hypertension, heart disease, lung disease, and smoking.¹⁹

The comorbid factors of diabetes mellitus, heart disease, and chronic kidney disease in COVID-19 patients could be the risk factors of death in this research, with a p-value of <0.05. Previous studies have described that the presence of common comorbidities increase COVID-19 patients risk. This result was similar to the meta-analysis study conducted by Mantovani *et al.*, who stated that the prevalence of diabetic patients hospitalized due to COVID-19 was 14.34%, and 11.06% in patients in Asian countries. Meanwhile, the prevalence in non-Asian countries was higher, which was 23.34%. The risk of worsening the condition to require treatment in hospital was greater in COVID-19 patients with pre-existing diabetes.²⁰ However, the specific comorbidity by which can lead to disease progression remain unknown in COVID-19 patients.²¹

For the hematologic parameters in this research, the leukocyte, neutrophil counts, lymphocyte count, and NLR demonstrated significantly different result between two groups. This research results were consistent with several previously published studies.^{22,23} On the other hand, the platelet count in this research was comparable between the groups of deceased and surviving patients. This was in contrast with the results of a meta-analysis that concluded by Lippi *et al.*, who showed that thrombocytopenia was associated with increasing severity risk and mortality of COVID-19.²⁴ Differences in pathophysiological mechanisms in each patient may lead to insignificant findings in this research. Many researchers have studied the changes in peripheral blood cell counts in COVID-19, and the results were that in infected patients, the white blood cell and neutrophil count increased, otherwise, the lymphocyte and platelet counts decreased.²⁵ In the other cases, coagulation abnormalities (prolonged PT and aPTT) and intravascular coagulopathy (DIC) were so correlated with low platelet count.²⁶

Figure 2. Kaplan-Meier survival curves white blood cell count (WBC), neutrophil count, lymphocyte count, neutrophil-lymphocyte ratio (NLR), platelet count, aPTT, prothrombin time, D-Dimer, and CRP.

Figure 2. (continued)

Table 4. Multivariate with Cox regression analysis.

	Crude HR (95% CI)	Crude p-value	Adjusted HR (95% CI)	Adjusted p-value
Age >65 years old: exists or not	2.05 (0.99-4.23)	0.051		
Hypertension: exists or not	1.16 (0.59-2.28)	0.647		
CKD: exists or not	2.76 (1.44-5.29)	0.002	1.64 (0.78-3.41)	0.185
Diabetes mellitus: exists or not	1.95 (1.03-3.71)	0.039	1.69 (0.84-3.39)	0.136
Coronary heart disease: exists or not	9.24 (3.20-26.67)	<0.001	11.56 (3.24-41.26)	<0.001
Platelet count: high or normal	0.971 (0.34-2.74)	0.956		
WBC count: high or normal	2.47 (1.29-4.69)	0.006	1.58 (0.76-3.29)	0.216
NLR: high or normal	2.91 (1.13-7.47)	0.026	1.81 (0.66-4.98)	0.247
C-reactive protein: high or normal	6.31 (0.86-46.30)	0.070		
Prothrombin time: high or normal	2.68 (1.04-6.91)	0.040	1.91 (0.67-5.39)	0.222
aPTT: high or normal	2.24 (0.53-9.34)	0.268		
D-Dimer	1.42 (0.34-5.93)	0.630		

The extreme inflammation is usually evidenced by elevated serum of CRP, IL-6, and PCT which indicate the increasing of COVID-19 severity.²⁷ High levels of CRP and procalcitonin in COVID-19 patients also associated with the progression of ARDS, myocardial injury, and death.^{27,28} The presence of secondary bacterial infection would be an additional explanation of this increase in inflammatory biomarkers. This is consistent with this research which showed that serum CRP levels were significantly higher in the cohort of deceased COVID-19 patients. Therefore, we believe that the use of CRP as a biomarker in monitoring the progress and severity of COVID-19 patients will be considerably beneficial.

D Dimer in our study were measured using ELFA (enzyme linked fluorescent assay) method and cut of point 0.410 µg/ml. Several literatures showed different cut off point for D Dimer. Poudel, 2021 with 182 subject research showed D Dimer level 1.5 µg/ml were an optimal cut off point to predict mortality.²⁹ While Zhang, 2020 with 343 subjects shows D Dimer level 2 µg/ml were an optimal cut off point.³⁰ Guan, 2020 in China with 1099 subjects showed that non-survivors had a significantly higher D-dimer (median: 2.12 µg/ml) than that of survivors (median: 0.61 µg/ml).³¹ This result could be due to differences in measurement methods as disclosed by Favaloro et al. who stated several things regarding the measurement and reporting quality of D-dimers such as the measurement method, cut-off value, or D-dimer unit [D-dimer unit (DDU)] can lead to different research results.³² Other factors in our study that can affect D dimer level were our patients were older with median age 52, comorbidities such as cardiovascular disease and liver disease. Liver disease can affects D Dimer elimination from blood. In this study D dimer level was also measured on admission, very early in disease course. The half-life of D-dimer was approximately 8 hours therefore, serial measurement of D-dimer will shows more information.

PT and aPTT prolongation may occur during severe COVID-19, yet the increase is not as high as what has been observed in bacterial sepsis and DIC. A meta-analysis conducted by Henry *et al.*²⁵ found that patients with severe and fatal COVID-19 had significantly higher coagulation parameters (especially PT) than patients with the non-severe ones. This is consistent with this research where there was an increase in aPTT, albeit insignificant, and a significant increase in PT with $p < 0.05$ in the group of deceased patients. Although it is not completely clear how SARS-CoV-2 activates the coagulation cascade, it may be associated as a by-product of cytokine storms.³³ Researchers detected a significant extension in coagulation tests in this research, consistent with previously published studies.^{25,34} The mechanism of these changes is still not fully explained, however, the extension of the coagulation test, *i.e.*, increased PT and aPTT, can be considered as a marker of disease severity and activation of the coagulation cascade and virus-induced cytokine storm.^{33,35}

For as much as this research was a retrospective study, several parametes were not completely listed such as level of ferritin, fibrinogen, procalcitonin, and IL-6, that we considered this as one of our research limitations. Since the development of complications that have occurred in patients are not thoroughly documented, we could not confidently say that inflammatory and coagulation factor disorders are more frequent in severe COVID-19. The only outcome measure of this research was patient mortality in hospital. Although researchers evaluated platelet count and D-dimers, the

International Society on Thrombosis and Hemostasis (ISTH) scores of the patients were not calculated, thus patients who had mild-to-moderate coagulation disorders could not be distinguished from who had a DIC.

Conclusion

This research indicates that hematologic and coagulation parameters are increased in the majority of COVID-19 patients and the group of deceased patients. As the neutrophil count and WBC increase, the lymphocyte count declines significantly along with the increase in disease severity. Coronary heart disease is an independent predictor of mortality.

Data availability

Underlying data

Figshare: Underlying data for 'Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia'. <https://doi.org/10.6084/m9.figshare.14673060>.

The project contains the following underlying data:

- Hema_Coagul_parameter_COVID.xlsx (main data).
- readme.docx (index).

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Consent

Written informed consent was received from the patients during hospitalization.

Acknowledgments

Researchers greatly appreciate to Dr. Joni Wahyuhadi., dr., Sp.BS(K) as the director in Dr. Soetomo General Teaching Hospital who has facilitated us in conducting research and Dr. Soebagjo Adi Soelistijo, dr.,Sp.PD.,KEMD.,FINASIM for giving us the opportunity to get research grant and facilitating us to collect data in internal medicine wards and intellectual discussion leading to research idea.

Ethical statement

The research ethics committee Dr. Soetomo General Academic Hospital (No: 0039/KEPK/VIII/2020).

References

1. Zhou P, Lou YX, Wang XG, *et al.*: **A pneumonia outbreak associated with a new coronavirus of probable bat origin.** *Nature.* 2020; **579**(7798): 270–3. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. WHO: **Clinical management of COVID-19, interim guidance 27 May 2020.** 2020. 55 p. [Reference Source](#)
3. (WHO) WHO: **Coronavirus disease COVID-2019 - Situation Report – 142 Data.** *Saf Risk Pharmacother.* 2020, **1**; **8**: 3–8. [Reference Source](#)
4. Gorbalenya AE, Baker SC, Baric RS, *et al.*: **Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group.** *bioRxiv.* 2020. [Publisher Full Text](#)
5. Ji W, Wang W, Zhao X, *et al.*: **Cross-species transmission of the newly identified coronavirus 2019-nCoV.** *J Med Virol.* 2020 Apr **19**; **92**(4): 433–40. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Khifzhon Azwar M, Setiati S: **COVID-19 and Indonesia.** *Acta Med Indones.* 2020; **52**(1): 84–9. [Reference Source](#)
7. Huang C, Wang Y, Li X, *et al.*: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet.* 2020 Feb; **395**(10223): 497–506. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Yang W, Cao Q, Qin L, *et al.*: **Clinical Characteristics and Imaging Manifestations of the 2019 novel coronavirus disease (COVID-19): A Multi-center study in Wenzhou City, Zhejiang, China.** *J Infect.* 2020; **80**(February): 388–93. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Yang W, Yan F: **Patients with RT-PCR-confirmed COVID-19 and Normal Chest CT.** *Radiology.* 2020 May; **295**(2): E3–E3. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Docherty AB, Harrison EM, Green CA, *et al.*: **Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol.** *medRxiv.* 2020; (April): 1–21. [Publisher Full Text](#)
11. Tang N, Li D, Wang X, *et al.*: **Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.** *J Thromb Haemost.* 2020; **18**(4): 844–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A, *et al.*: **The Role of Anticoagulation in COVID-19-Induced Hypercoagulability.** *Curr Cardiol Rep.* 2020; **22**(7): 1–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Shang W, Dong J, Ren Y, *et al.*: **The value of clinical parameters in predicting the severity of COVID-19.** *J Med Virol.* 2020; **92**(10): 2188–92. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Isbaniah F: **Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19).** *Germs.* 2020: 0–115. [Reference Source](#)
15. Chan JFW, Yuan S, Kok KH, *et al.*: **A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-Person Transmission: a Study of a Family Cluster.** *Lancet.* 2020;

- 395(February): 514–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Zhu N, Zhang D, Wang W, *et al.*: **A Novel Coronavirus from Patients with Pneumonia in China, 2019.** *N Engl J Med.* 2020 Feb 20; **382**(8): 727–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 17. Zhou F, Yu T, Du R, *et al.*: **Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study.** *Lancet.* 2020; **395**(10229): 1054–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Wenham C, Smith J, Morgan R: **COVID-19: the gendered impacts of the outbreak.** *Lancet.* 2020; **395**(10227): 846–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 19. Lancet T: **The gendered dimensions of COVID-19.** *Lancet.* 2020; **395**(10231): 1168.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Mantovani A, Byrne CD, Zheng M: **Diabetes as a Risk Factor for Greater COVID-19 Severity and in-Hospital Death: A Meta-Analysis of Observational Studies.** *Nutr Metab Cardiovasc Dis.* 2020; **30**(January): 1236–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Wang B, Li R, Lu Z, *et al.*: **Does comorbidity increase the risk of patients with COVID-19.** *Aging (Albany NY).* 2020; **12**(7): 6049–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Liu Y, Du X, Chen J, *et al.*: **Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19.** *J Infect.* 2020; **81**(January): e6–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Tatum D, Taghavi S, Houghton A, *et al.*: **Neutrophil-to-Lymphocyte Ratio and Outcomes in Louisiana COVID-19 Patients.** *Shock.* 2020; **54**(5): 652–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Lippi G, Plebani M, Michael B: **Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis.** *Clin Chim Acta.* 2020; **506**(January): 145–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Henry BM, de Oliveira MHS, Benoit S, *et al.*: **Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.** *Clin Chem Lab Med.* 2020; **58**(7): 1021–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Bao C, Tao X, Cui W, *et al.*: **SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients.** *Exp Hematol Oncol.* 2020; **9**(16): 1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Chen G, Wu D, Guo W, *et al.*: **Clinical and immunological features of severe and moderate coronavirus disease 2019.** *J Clin Invest.* 2020; **130**(5): 2620–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Huang I, Pranata R, Lim MA, *et al.*: **C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis.** *Ther Adv Respir Dis.* 2020 Jan 2; **14**(6): 175346662093717.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Poudel A, Poudel Y, Adhikari A, *et al.*: **D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19.** *PLoS One.* 2021; **16**(8): e0256744.
[Publisher Full Text](#)
 30. Zhang L, Yan X, Fan Q, *et al.*: **D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19.** *J Thromb Haemost.* 2020 Jun; **18**(6): 1324–1329.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. Guan WJ, Ni ZY, Hu Y, *et al.*: **China Medical Treatment Expert Group for C. Clinical characteristics of coronavirus disease 2019 in China.** *N Engl J Med.* 2020; **382**(18): 1708–1720.
 32. Favaloro EJ, Thachil J: **Reporting of D-dimer data in COVID-19: Some confusion and potential for misinformation.** *Clin Chem Lab Med.* 2020; **58**(8): 1191–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Marietta M, Coluccio V, Luppi M: **COVID-19, coagulopathy and venous thromboembolism: more questions than answers.** *Intern Emerg Med.* 2020; **15**(8): 1375–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Iba T, Levy JH, Levi M, *et al.*: **Coagulopathy in COVID-19.** *J Thromb Haemost.* 2020; **18**(9): 2103–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Jose RJ, Manuel A: **COVID-19 cytokine storm: the interplay between inflammation and coagulation.** *Lancet Respir Med.* 2020 Jun; **8**(6): e46–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 3

Reviewer Report 01 December 2021

<https://doi.org/10.5256/f1000research.79610.r101465>

© 2021 Lattanzi S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Simona Lattanzi

Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy

The Authors did not address any of the issues raised in my previous report. The issues should be considered in revising the manuscript.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neurology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 02 Dec 2021

Siprianus Ugroseno Yudho Bintoro

We appreciate your constructive comments. Levels of interleukins are not available because other research groups have studied at our general hospital.

Thank you for your suggestion.

Inflammation Biomarker is not the only marker of infection. Interleukin-6 (IL-6) and CRP are critical inflammation biomarkers that may be implicated in the diagnosis, risk stratification, and prognosis of patients with Acute Myocardial Infarct. IL-6 expression is shown to be elevated in induced myocardial infarction by transcatheter ablation of septal hypertrophy, suggesting its diagnostic role (1). Additionally, CRP and IL-6 are both significantly upregulated in acute coronary syndrome (2). The IL-6 concentration, independent of the already established predictors, is also related to adverse cardiac events

Cancer-associated inflammation occurs in the tumour microenvironment and the systemic circulation and is correlated with disease progression and prognosis in many cancers. Numbers of circulating blood cells, including neutrophils, lymphocytes, platelets, and levels of circulating proteins, including C-reactive protein (CRP) and interleukins (ILs) associated with inflammatory responses, are critical factors in the recognition of pathways for tumorigenesis and growth.

Platelet-to-lymphocyte has been shown to be a useful metric for determining the prognosis of a variety of cancers in patients. Increased Platelet Lymphocyte Ratio (PLR) levels are a significant prognostic factor for poor prognosis in terms of OS in patients with gastric, colorectal, ovarian, hepatocellular, and lung cancers. Raungkaewamee et al. observed that patients with a PLR of less than 200 had improved survival [progression-free survival (PFS), $p = 0.003$ and OS, $p = 0.002$] (3).

An elevated Neutrophil Lymphocyte Ratio (NLR) is associated with advanced-stage cancer, high histological grade, and metastasis (4); moreover, an elevated NLR is also an independent prognostic factor of coronary artery disease, hypertension, chronic kidney disease, diabetes, heart failure, cerebrovascular disease, and peripheral arterial disease. NLR has been shown to be sensitive to atherosclerotic risk factors such as smoking, alcohol consumption, hypercholesterolemia, and metabolic syndrome (5).

C-reactive protein is an acute phase non-specific inflammatory reactant; it's released by the liver in response to increased levels of IL-6 released by activated macrophages, though it has also been found that IL-1 and TNF can also stimulate CRP synthesis. There remains a need for larger studies to be conducted to define the importance of CRP as a biomarker for informing cancer staging and prognosis (6).

References:

1. Liebetrau C., Hoffmann J., Dörr O., et al. Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction. *Circulation Research*. 2015;116(5):867–875. DOI: 10.1161/circresaha.116.304653. [PubMed] [CrossRef] [Google Scholar]
2. Kaminska J., Koper O. M., Siedlecka-Czykier E., Matowicka-Karna J., Bychowski J., Kemonia H. The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes. *Saudi Journal of Biological Sciences*. 2018;25(7):1263–1271. [PMC free article] [PubMed] [Google Scholar]
3. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. *J Gynecol Oncol* (2012) 23:265–73. doi:10.3802/jgo.2012.23.4.265
4. Wang Y, Liu P, Xu Y, Zhang W, Tong L, Guo Z, et al. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. *Cancer Chemother Pharmacol* (2015) 75:255–62. doi:10.1007/s00280-014-2622-6
5. Balta S, Demirkol S, Kucuk U, Sarlak H, Kurt O, Arslan Z. Neutrophil to lymphocyte ratio may predict mortality in breast cancer patients. *J Breast Cancer* (2013) 16:354–5. doi:10.4048/jbc.2013.16.3.354
6. Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-reactive protein is an

important biomarker for prognosis tumour recurrence and treatment response in adult solid tumors: a systematic review. *PLoS One* (2015) 10:e0143080.
doi:10.1371/journal.pone.0143080

Competing Interests: No competing interests were disclosed.

Reviewer Report 30 November 2021

<https://doi.org/10.5256/f1000research.79610.r101467>

© 2021 Husin A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Azlan Bin Husin

¹ Hospital Universiti Sains Malaysia, Kubang Kerian, Malaysia

² School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia

Congratulations, all comments has been addressed well.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical hematology, benign hematology, malignant hematology, autologous hematopoietic stem cell transplant

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 2

Reviewer Report 16 November 2021

<https://doi.org/10.5256/f1000research.77444.r100136>

© 2021 Lattanzi S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Simona Lattanzi

Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy

This was a retrospective study aiming to evaluate the clinical and laboratory predictors of

mortality in COVID-19 patients.

The study is interesting and provides useful information in clinical practice. There are, however, some issues that need to be further addressed.

Were levels of interleukins available? Could you explore any correlations with the other identified predictors?

There is increasing evidence that easily obtainable laboratory biomarkers can have a predictive role and be used for diagnosis and outcome prediction in a variety of medical conditions not limited to infectious pathologies, but also including major cardiac events (ref 1), cerebral hemorrhage (ref 2), ischemic stroke (ref 3; ref 4), and cancers (ref 5; ref 6). In light of the suggested evidence, please put the study findings into the current research context by adding a brief synthesis about the meaning and wide potentialities of easy to obtain and inexpensive serum biomarkers in everyday clinical practice.

References

1. Tamhane UU, Aneja S, Montgomery D, Rogers EK, et al.: Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol.* 2008; **102** (6): 653-7 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Lattanzi S, Cagnetti C, Rinaldi C, Angelocola S, et al.: Neutrophil-to-lymphocyte ratio improves outcome prediction of acute intracerebral hemorrhage. *Journal of the Neurological Sciences.* 2018; **387**: 98-102 [Publisher Full Text](#)
3. Lattanzi S, Norata D, Divani AA, Di Napoli M, et al.: Systemic Inflammatory Response Index and Futile Recanalization in Patients with Ischemic Stroke Undergoing Endovascular Treatment. *Brain Sci.* 2021; **11** (9). [PubMed Abstract](#) | [Publisher Full Text](#)
4. Świtońska M, Piekus-Słomka N, Słomka A, Sokal P, et al.: Neutrophil-to-Lymphocyte Ratio and Symptomatic Hemorrhagic Transformation in Ischemic Stroke Patients Undergoing Revascularization. *Brain Sci.* 2020; **10** (11). [PubMed Abstract](#) | [Publisher Full Text](#)
5. Howard R, Kanetsky P, Egan K: Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. *Scientific Reports.* 2019; **9** (1). [Publisher Full Text](#)
6. Xie Q, Chen P, Hu W, Sun P, et al.: The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. *Journal of Translational Medicine.* 2018; **16** (1). [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neurology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 28 September 2021

<https://doi.org/10.5256/f1000research.77444.r94904>

© 2021 Rachman A et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Andhika Rachman

Department of Hematology and Medical Oncology, University of Indonesia, Jakarta, Indonesia
Bayu Rumondor
Kebayoran Baru General Hospital Jakarta, South Jakarta, Indonesia

There are no further comments. Thank you for the revision

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunology, Cancer thrombosis, and Platelets

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 31 August 2021

<https://doi.org/10.5256/f1000research.57221.r91683>

© 2021 Husin A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Azlan Bin Husin

¹ Hospital Universiti Sains Malaysia, Kubang Kerian, Malaysia

² School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia

1. Policy or criteria for hospital admission is important information to be included or at least discussed
2. Inclusion of patients who were not having COVID19 is not relevant in this research, unless author want to compare between positive vs negative group
3. This study used secondary data retrieved in respective manner; hence the documentation for informed consent from each patients is irrelevant
4. Operational definition for relevant co-morbidities were not available eg: thyroid disease (hypothyroid or hyperthyroid) or coronary artery disease (was it based on coronary angiogram or ECG or echocardiogram only or self declaration), etc.
5. Mortality should be defined - whether it is overall or specific of any term
6. Should look into more meaningful key points to compare between this study results with other published reports.

Eg: a) Regarding age: comparing mean age is better. While discussing on this point it is important to consider relevant differences in study population (eg: hospital admission criteria that may include age, presence of co-morbidity etc)

7. Some statements were too strong and not supported by cited reference e.g. paragraph 2 (regarding gender issues), paragraph 3 (on elderly and diabetes), and paragraph 4 (about

pathophysiologic mechanism) of the discussion.

8. Discussion on D-dimer should be supported by comparing the method and cut off point used in this study versus with other published data. Should also look into possible confounding factors like superimposed infection or may be smaller number of patients

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

No

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

No

Are the conclusions drawn adequately supported by the results?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: clinical hematology, benign hematology, malignant hematology, autologous hematopoietic stem cell transplant

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 31 Aug 2021

Siprianus Ugroseno Yudho Bintoro

Dear reviewer,

Thank you for reviewing and sending the feedback. We are going to revise it real soon.

warm regards,

Research Team

Competing Interests: No competing interests were disclosed.

Author Response 18 Nov 2021

Siprianus Ugroseno Yudho Bintoro

Comment 1:

Policy or criteria for hospital admission were compliant with hospital policy which are: confirmed or suspected Covid-19, who are symptomatic plus any of following criteria.

1. Age > 65 years.
2. Clinical or radiologic evidence of pneumonia.
3. O₂ saturation Spo₂ < 99 %.
4. Acute respiratory distress syndrome.
5. COPD
6. CKD
7. Acute complication of diabetes mellitus.
8. Obesity (BMI ≥ 40).
9. Acute malignancy.
10. Other to illness by physician description.

We included inclusion and exclusion criteria in Methods paragraph 2 in the revised version.

Comment 2:

We appreciate your very helpful comments. We included the probable patients to show the magnitude of Covid-19 probable cases in our referral hospital.

Comment 3:

We appreciate your very helpful comment. However we already have the informed consent to use patient's secondary administrative during their time of admission.

Comment 4:

Thank you for your very helpful comment. Comorbidities were recorded at admission by attending clinical staff (board certified interns), either by history taking, records from previous visits in our hospital, or previous laboratory result assessment, or patient reporting. We added it in the manuscript: Methods paragraph 2

Comment 5:

Thank you for your suggestion. In patients with confirmed Covid-19 we use the definition of mortality based on the WHO definition: death resulting from a clinically compatible illness in a probable or confirmed Covid-19 case, unless there is a clear alternative cause of death that cannot be related to Covid-19 (e.g trauma). There should be no periode of complete recovery between the illness and death.

Comment 6:

We appreciate your comment, we revised our manuscript in Discussion, paragraphs 1 to 4.

Significant differences were found in the demographic and clinical variables, and hematologic and coagulation parameters between the deceased and surviving COVID-19

patients. We included age in the risk factor for COVID-19 mortality, whereas the age had a p-value <0.05. The age factor appeared to be crucial for the outcome of COVID-19. The average age of the deceased patients was 58 years old and was significantly older than the surviving patients. This was in accordance with previous studies that older age has been reported as an important independent predictor of mortality in SARS-Cov2.^{15,16} Increasing age also increased the percentage of COVID-19 mortality, the age-dependent defects in T-cell and B-cell function could lead to a deficiency in control of viral replication and more prolonged proinflammatory responses, potentially leading to poor outcome.¹⁷

Comment 7:

Gender was suspected to be a risk factor for mortality in COVID-19 patients, which was higher for men than for women. This is thought to be due to differences in the immunological systems of men and women, differences in lifestyle, and the prevalence of smoking.¹⁸ In this research, although statistically insignificant, the percentage of the number of male COVID-19 patients was higher, both overall and in the group of deceased patients. The higher mortality rates were associated with the higher chronic comorbidities in men, e.g., diabetes mellitus, kidney disease, hypertension, heart disease, lung disease, and smoking.¹⁹

The comorbidity factors of diabetes mellitus, heart disease, and chronic kidney disease in COVID-19 patients could be the risk factors of death in this research, with a p-value of <0.05. Previous studies have described that the presence of common comorbidities increase COVID-19 patients risk. This result was similar to the meta-analysis study conducted by Mantovani *et al.*, who stated that the prevalence of diabetic patients hospitalized due to COVID-19 was 14.34%, and 11.06% in patients in Asian countries. Meanwhile, the prevalence in non-Asian countries was higher, which was 23.34%. The risk of worsening the condition to require treatment in hospital was greater in COVID-19 patients with pre-existing diabetes.²⁰ However, the specific comorbidity by which can lead to disease progression remains unknown in COVID-19 patients.²¹

For the hematologic parameters in this research, the leukocyte, neutrophil counts, lymphocyte count, and NLR demonstrated significantly different result between two groups. These research results were consistent with several previously published studies.^{22,23} On the other hand, the platelet count in this research was comparable between the groups of deceased and surviving patients. This was in contrast with the results of a meta-analysis that concluded by Lippi *et al.*, who showed that thrombocytopenia was associated with increasing severity risk and mortality of COVID-19.²⁴ Differences in pathophysiological mechanisms in each patient may lead to insignificant findings in this research. Many researchers have studied the changes in peripheral blood cell counts in COVID-19, and the results were that in infected patients, the white blood cell and neutrophil count increased, while the lymphocyte and platelet counts decreased.²⁵ In the other cases, coagulation abnormalities (prolonged PT and aPTT) and intravascular coagulopathy (DIC) were so correlated with low platelet count.²⁶

Comment 8:

Thank you for your very helpful comment. We revised the manuscript in Discussion paragraph 6.

D-Dimer in our study were measured using ELFA (enzyme linked fluorescent assay) method and cut off point 0.410 µg/ml. Several literatures showed different cut off point for D-Dimer. Poudel *et al.*, with 182 subjects, showed D-Dimer levels of 1.5 µg/ml were an optimal cut off point to predict mortality. While Zhang, 2020, with 343 subjects, shows D-Dimer level 2 µg/ml were an optimal cut off point. Guan, 2020 in China, with 1099 subjects, showed that non-survivors had a significantly higher D-dimer (median: 2.12 µg/ml) than that of survivors (median: 0.61 µg/ml). This result could be due to differences in measurement methods as disclosed by Favaloro *et al.* who stated several things regarding the measurement and reporting quality of D-dimers, such as the measurement method, cut-off value, or D-dimer unit [D-dimer unit (DDU)] can lead to different research results.³⁰

Other factors in our study that can affect D-dimer level were our patients were older with median age 52, comorbidities such as cardiovascular disease and liver disease. Liver disease can affect D-Dimer elimination from blood. In this study D-dimer level was also measured on admission, very early in disease course. The half-life of D-dimer was approximately 8 hours therefore, serial measurement of D-dimer will shows more information

Competing Interests: No competing interests were disclosed.

Reviewer Report 27 August 2021

<https://doi.org/10.5256/f1000research.57221.r91679>

© 2021 Rachman A *et al.* This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Andhika Rachman

Department of Hematology and Medical Oncology, University of Indonesia, Jakarta, Indonesia

Bayu Rumondor

Kebayoran Baru General Hospital Jakarta, South Jakarta, Indonesia

The aim of this study is to evaluate and analyze risk factors of death, hematological and coagulation factors for COVID patients at RSUD Dr. Soetomo Surabaya. The parameters used in this manuscript were Hb, WBC, Neu#, lim#, NLR, platelet count, aPTT, PT, D-dimer, and CRP.

1. The statement "significantly different in the deceased group" might need to be rephrased to make it more clear.
2. In the discussions section under "survival analysis" it is stated that "leukopenia, leukocytosis, neutrophilia, high NLR, CRP and PT correlates with survival". This might confuse the readers. The writers might need to rephrase the statements to make it more in line with the abstract and with following statements.
3. The writers might need to detail the inclusion criteria used in the study. The writers stated

that probable patients are included in the study, but the analysis is aimed more towards confirmed cases (the 217 subjects). In figure 1, it is indicated that 217 confirmed patients with complete data proceeded to statistical analysis.

4. The covid-19 degree of severity of the patients should be explained in more detail. This might help the reader to contextualize the term "non-ICU".
5. Kruskal Wallis method of analysis was not explained in the methods section.
6. The table 2 "comparison of the laboratory results in deceased and survived patients" may need some explanations. One example is that the writer used "above-normal result percentages".
7. Some grammatical errors might need to be addressed in the article.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: immunology, cancer thrombosis and platelet

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 28 Aug 2021

Siprianus Ugroseno Yudho Bintoro

Dear Reviewer,

Thank you for reviewing and sending the feedback. We are going to revise it real soon.

Warm regards,

Research Team

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research